NOT-AI-24-070: Notice of Immediate Expiration of RFA-AI-24-045, Promoting Innovative Research in Treponema pallidum Pathogenesis (R21 Clinical Trial Not Allowed)

Notice of Immediate Expiration of RFA-AI-24-045, Promoting Innovative Research in Treponema pallidum Pathogenesis (R21 Clinical Trial Not Allowed)

Notice Number:

NOT-AI-24-070

Key Dates

Release Date:

July 19, 2024

Related Announcements

July 08, 2024 - Promoting Innovative Research in Treponema pallidum Pathogenesis (R21 Clinical Trial Not Allowed). See NOFO RFA-AI-24-045.

Issued by

National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

The purpose of this Notice is to inform the extramural community that RFA-AI-24-045, Promoting Innovative Research in Treponema pallidum Pathogenesis (R21 Clinical Trial Not Allowed) will be expired, effective immediately, due to an error in the instructions. NIAID plans to publish a Notice of Funding Opportunity (NOFO) with the same scientific focus in the near future.

Inquiries

Please direct all inquiries to:

Leah R. Vincent, PhD
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 301-761-7365
Email: leah.vincent@nih.gov